Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbachol
Drug ID BADD_D00355
Description Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932.[A226315] Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.[L30245]
Indications and Usage Carbamoylcholine is indicated to induce miosis for surgery and to reduce intraocular pressure elevations in the first 24 hours after cataract surgery.[L30245]
Marketing Status approved
ATC Code N07AB01; S01EB02
DrugBank ID DB00411
KEGG ID D00524
MeSH ID D002217
PubChem ID 5831
TTD Drug ID D0U7BW
NDC Product Code 65732-131; 0065-0023
UNII 8Y164V895Y
Synonyms Carbachol | Carbocholine | Carbacholine | Miostat | Jestryl | Carbamann | Doryl | Carbastat | Carboptic | Isopto Carbachol | Carbachol, Isopto | Carbamylcholine | Carbamoylcholine
Chemical Information
Molecular Formula C6H15N2O2.Cl
CAS Registry Number 51-83-2
SMILES C[N+](C)(C)CCOC(=O)N.[Cl-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Bladder discomfort20.02.02.019--Not Available
Bradycardia02.03.02.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Ciliary muscle spasm17.17.02.002; 06.05.03.001--Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Corneal degeneration06.06.03.001--Not Available
Corneal opacity06.06.03.005--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspepsia07.01.02.001--
Eye irritation06.04.05.003--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Iritis10.02.01.022; 06.04.03.002--Not Available
Loss of consciousness17.02.04.004--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Pain08.01.08.004--
Pruritus23.03.12.001--
Retinal detachment12.01.04.004; 06.09.03.003--
Salivary hypersecretion07.06.01.009--Not Available
Shock24.06.02.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene